Loic Chaigneau
Overview
Explore the profile of Loic Chaigneau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
996
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Drozd C, Jacquinot Q, Paget-Bailly S, Mansi L, Paillard M, Bazan F, et al.
BMJ Support Palliat Care
. 2024 Dec;
PMID: 39740960
Background: Although the benefit of supportive care in the postcancer period is now well demonstrated, its implementation in the patient journey remains challenging. This article describes the development, since 2015...
2.
Blay J, Penel N, Toulmonde M, Valentin T, Chaigneau L, Rios M, et al.
Eur J Cancer
. 2024 Jul;
208:114228.
PMID: 39018632
Rationale: We report a phase II trial (OSAD93) testing CDDP with ifosfamide (IFO), without doxorubicin in neoadjuvant phase, in adult osteosarcoma with a 25 years follow-up. Patients And Methods: This...
3.
El Kaddissi A, Vernerey D, Falcoz A, Mansi L, Bazan F, Chaigneau L, et al.
Clin Breast Cancer
. 2024 Jul;
24(7):e622-e632.e5.
PMID: 38972830
Context And Aims: Eribulin is used in taxane and anthracycline refractory HER2-negative metastatic breast cancers (MBC). Patients treated in pivotal clinical trials achieved low survival rates, therefore, the identification of...
4.
Gantzer J, Toulmonde M, Severac F, Chamseddine A, Charon-Barra C, Vinson C, et al.
Cancer
. 2024 Mar;
130(13):2304-2314.
PMID: 38470379
Background: Perivascular epithelioid cell neoplasms (PEComas) encompass a heterogeneous family of mesenchymal tumors. Previously described clinicopathologic features aimed at distinguishing benign from malignant variants but lacked prognostic value. Methods: This...
5.
Drozd C, Curtit E, Jacquinot Q, Marquine C, Mansi L, Chaigneau L, et al.
BMC Cancer
. 2023 May;
23(1):449.
PMID: 37198562
Background: Up to 70% of breast cancer patients report symptoms of insomnia during and after treatment. Despite the ubiquity of insomnia symptoms, they are under-screened, under-diagnosed and poorly managed in...
6.
Lebreton C, Meeus P, Genestie C, Croce S, Guyon F, Llacer Moscardo C, et al.
Bull Cancer
. 2023 Mar;
110(7-8):844-854.
PMID: 36990895
Low-grade endometrial stromal sarcoma (LG-ESS) accounts for approximately 15% of all uterine sarcomas. Median age of patients is around 50 years and half of the patients are premenopausal. In all,...
7.
Kubicek P, Cesne A, Lervat C, Toulmonde M, Chevreau C, Duffaud F, et al.
BMC Cancer
. 2023 Jan;
23(1):69.
PMID: 36670431
Background: The initial management of patients with sarcoma is a critical issue. We used the nationwide French National Cancer Institute-funded prospective sarcoma database NETSARC to report the management and oncologic...
8.
Chaigneau L, Jary M, Nerich V, Hervieu A, Aubry S, Charon Barra C, et al.
Oncology
. 2022 Oct;
100(12):633-644.
PMID: 36283345
Introduction: Soft tissue sarcomas (STSs) are a rare and heterogenous group of tumors, with poor prognostic, judging from their frequency to relapse. Few drugs are available after the conventional first-line...
9.
Jacquinot Q, Meneveau N, Falcoz A, Bouhaddi M, Roux P, Degano B, et al.
Front Cardiovasc Med
. 2022 Oct;
9:1000846.
PMID: 36211552
Background: Trastuzumab is used, alone or in conjunction with standard chemotherapy, to treat HER2-positive breast cancer (BC). Although it improves cancer outcomes, trastuzumab. can lead to cardiotoxicity. Physical exercise is...
10.
Fayet Y, Chevreau C, Decanter G, Dalban C, Meeus P, Carrere S, et al.
Cancers (Basel)
. 2022 Jun;
14(11).
PMID: 35681600
The national reference network NETSARC+ provides remote access to specialized diagnosis and the Multidisciplinary Tumour Board (MTB) to improve the management and survival of sarcoma patients in France. The IGéAS...